Skip to main content

RT @RichardPAConway: Kavanaugh et al. TYK2i deucravacitinib in PsA. Nice breakdown of MDA and its components over 16 wee

Nov 14, 2022 6:43 am
Social Author Name
Richard Conway
Tweet Content
Kavanaugh et al. TYK2i deucravacitinib in PsA. Nice breakdown of MDA and its components over 16 weeks. MDA achieved 23-24% with deucravacitinib at 16 weeks vs 8% with placebo @RheumNow #ACR22 Abstr#2136 https://t.co/9IG8CeZzMh https://t.co/Vg8E20y7Z8
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×